Philip Morris has cut its annual profit forecast for the second time in two months, and the CEO is pointing at a familiar list of pressures: higher energy costs tied to the conflict in the Middle East, currency swings working against the company's global revenues, and consumers who are simply spending less.

The revised forecast puts 2026 earnings at $8.31 to $8.46 per share, down from a prior range of $8.36 to $8.51. That may sound like a rounding error, but analysts had already pegged expectations near the middle of the old range, and two downward revisions in quick succession is a signal that the ground is shifting faster than the company expected. Shares slid about 1% before Tuesday's opening bell.

The pricing problem

Here is the part that matters beyond the quarterly numbers. CEO Jacek Olczak said at a Deutsche Bank conference that price increases are "not always fully absorbed" in today's more competitive market. That is a careful way of saying that Philip Morris can raise prices to cover rising costs, but customers are pushing back or walking away rather than just paying more.

For a company that has spent years positioning itself as the premium end of a category it is helping to create, that is uncomfortable territory. Zyn nicotine pouches, the product that became a cultural shorthand for the smokeless-nicotine boom, carries a steep price premium over competitors. That premium is now a liability.

The company's answer is Zyn Ultra, a newly released product line priced at a lower cost per pouch than the flagship range. The goal is to hold onto users who might otherwise try a cheaper competing brand. The tradeoff is obvious: more volume, but at lower margins, precisely when margins are already under pressure.

What the FDA move actually means

Olczak framed recent FDA decisions to relax enforcement on unauthorized vaping and nicotine pouches as a "net positive." The practical effect is reduced regulatory uncertainty around Zyn, which had faced a real question earlier this year about whether it could continue operating freely in the U.S. market. That question is now less acute, which removes one ceiling on the category's growth.

But regulatory breathing room and pricing power are different things. Even with a friendlier FDA posture, Philip Morris still has to compete in a market where the consumer is cautious and rivals are undercutting on price.

The bigger pattern

Philip Morris is caught between two forces that are pulling in opposite directions. Its strategy for the past several years has been to pivot away from cigarettes toward smoke-free products, positioning them as both healthier and premium. That positioning worked when consumer spending was loose and competitors were few. Now both conditions have changed.

The energy cost pressure is partly tied to the wider disruption from the Iran conflict, which has pushed energy prices higher across global supply chains. That is not specific to tobacco, but it lands harder on companies that were already managing a costly product transition and relying on price increases to fund it.

Japan offers a preview of what that tension looks like in practice. Philip Morris said recent price increases there, driven by excise tax changes, have weighed on category growth even though market share has held for now. Market share today and volume growth tomorrow are different metrics, and the Japanese experience suggests that sustained price pressure does eventually slow the whole category down, not just one brand.

For the roughly 1.7 million Americans who use Zyn regularly, the immediate consequence is straightforward: a cheaper version of the product is coming, which means more choice at the shelf. For Philip Morris shareholders, the question is whether selling more pouches at lower margins is a business model that scales. The company is betting it is. Wall Street, down 1% at the open, is not yet convinced.